These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 10395996)

  • 1. Control of cytomegalovirus disease in renal transplant patients treated with prednisone, azathioprine and cyclosporine using intensive monitoring and decreased immunosuppression.
    Gómez E; de Oña M; Mélon S; Alvarez R; Laures A; Rodríguez M; Pobes A; Alvarez-Grande J
    Nephron; 1999; 82(3):238-45. PubMed ID: 10395996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytomegalovirus risk factors in renal transplantation with modern immunosuppression.
    Bataille S; Moal V; Gaudart J; Indreies M; Purgus R; Dussol B; Zandotti C; Berland Y; Vacher-Coponat H
    Transpl Infect Dis; 2010 Dec; 12(6):480-8. PubMed ID: 20629971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Failure of ganciclovir prophylaxis to completely eradicate CMV disease in renal transplant recipients treated with intense anti-rejection immunotherapy.
    Isenberg AL; Shen GK; Singh TP; Hahn A; Conti DJ
    Clin Transplant; 2000 Jun; 14(3):193-8. PubMed ID: 10831076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of triple-therapy with double-therapy immunosuppression in cadaveric renal transplantation.
    Bowman JS; Angstadt JD; Waymack JP; Jaffers GJ
    Transplantation; 1992 Mar; 53(3):556-9. PubMed ID: 1312752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
    Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J
    Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simultaneous quadruple immunosuppression with cyclosporine induction therapy in high risk renal transplant recipients.
    Indudhara R; Khauli RB; Menon M; Stoff JS
    J Urol; 1994 Aug; 152(2 Pt 1):307-11. PubMed ID: 8015058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunosuppression in live-related donor renal transplantation.
    Iman A; Rao M; Juneja R; Jacob CK
    Natl Med J India; 2001; 14(2):75-80. PubMed ID: 11396322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of treatment with cyclosporine versus azathioprine on incidence and severity of cytomegalovirus infection posttransplantation.
    Bia MJ; Andiman W; Gaudio K; Kliger A; Siegel N; Smith D; Flye W
    Transplantation; 1985 Dec; 40(6):610-4. PubMed ID: 3000031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of immunosuppressive regimen on the incidence and characteristics of cytomegalovirus infection in heart transplantation: a single-center experience with preemptive therapy.
    De Santo LS; Romano G; Mastroianni C; Roberta C; Della Corte A; Amarelli C; Maiello C; Giannolo B; Marra C; Ragone E; Grimaldi M; Utili R; Scardone M; Cotrufo M
    Transplant Proc; 2005; 37(6):2684-7. PubMed ID: 16182784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Factors influencing prevalence and clinical course of cytomegalovirus (CMV) infection in kidney transplant patients].
    Szymczakiewicz-Multanowska AM; Kuźniewski M; Zawilińska B; Zgórniak-Nowosielska I; Uracz D; Ignacak E; Betkowska-Prokop A; Sułowicz W
    Przegl Lek; 2001; 58(7-8):772-7. PubMed ID: 11769385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of early cyclosporine levels on kidney allograft rejection.
    Johnson EM; Canafax DM; Gillingham KJ; Humar A; Pandian K; Kerr SR; Najarian JS; Matas AJ
    Clin Transplant; 1997 Dec; 11(6):552-7. PubMed ID: 9408683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of acute cellular rejection after azathioprine withdrawal in stable renal allograft recipients on cyclosporine, azathioprine, and prednisone.
    Fabrega AJ; Roy G; Reynolds L; Corwin C; Hunsicker L
    Transplant Proc; 1998 Jun; 30(4):1335-6. PubMed ID: 9636543
    [No Abstract]   [Full Text] [Related]  

  • 13. Weaning of immunosuppression in liver transplant recipients.
    Mazariegos GV; Reyes J; Marino IR; Demetris AJ; Flynn B; Irish W; McMichael J; Fung JJ; Starzl TE
    Transplantation; 1997 Jan; 63(2):243-9. PubMed ID: 9020325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of cyclophosphamide, azathioprine, and cyclosporine (ciclosporin) as adjuvant drugs in pemphigus vulgaris.
    Olszewska M; Kolacinska-Strasz Z; Sulej J; Labecka H; Cwikla J; Natorska U; Blaszczyk M
    Am J Clin Dermatol; 2007; 8(2):85-92. PubMed ID: 17428113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunosuppression without prednisone after liver transplantion is safe and associated with normal early graft function: preliminary results of a randomized study.
    Tisone G; Angelico M; Palmieri G; Pisani F; Baiocchi L; Vennarecci G; Anselmo A; Orlando G; Negrini S; Casciani CU
    Transpl Int; 1998; 11 Suppl 1():S267-9. PubMed ID: 9664993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction therapy with cyclosporine without cytolytic agents results in a low incidence of acute rejection without significant renal impairment in heart transplant patients.
    Jazzar A; Fagiuoli S; Sisson S; Zuhdi N; Cooper DK
    Clin Transplant; 1995 Aug; 9(4):334-9. PubMed ID: 7579743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypogammaglobulinemia after heart transplantation: use of intravenous immunoglobulin replacement therapy in relapsing CMV disease.
    Sarmiento E; Fernàndez-Yáñez J; Muñoz P; Palomo J; Rodríguez-Molina JJ; Bermejo J; Catalan P; Bouza E; Fernández-Cruz E; Carbone J
    Int Immunopharmacol; 2005 Jan; 5(1):97-101. PubMed ID: 15589466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis.
    Reischig T; Jindra P; Hes O; Bouda M; Kormunda S; Treska V
    Transplantation; 2009 Feb; 87(3):436-44. PubMed ID: 19202451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimization of immunosuppression by switching from azathioprine to enteric-coated mycophenolate sodium in stable kidney transplant patients.
    Gutiérrez Sánchez MJ; Morales Cerdán JM; Belmonte AA
    Transplant Proc; 2009; 41(6):2320-2. PubMed ID: 19715907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of immunosuppression therapy following heart transplantation: pretransfusion/azathioprine/ATG/prednisone versus cyclosporine/prednisone.
    Barnhart GR; Goldman MH; Hastillo A; Szentpetery S; Wolfgang T; Thompson J; Mohanakumar T; Katz MR; Rider S; Hanrahan J
    J Heart Transplant; 1985; 4(4):381-4. PubMed ID: 3916511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.